Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048020 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
A Phase 2 study of Human Papilloma Virus Infection and Stage III Squamous Cell Carcinoma of the Oropharynx, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02048020 is a Phase 2 study of Human Papilloma Virus Infection and Stage III Squamous Cell Carcinoma of the Oropharynx that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 26 participants, below the 1,422-participant average among 4 other Human Papilloma Virus Infection trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02048020, a Phase 2 study of Human Papilloma Virus Infection and Stage III Squamous Cell Carcinoma of the Oropharynx, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well paclitaxel and carboplatin before radiation therapy with paclitaxel works in treating human papillomavirus (HPV)-positive patients with stage III-IV oropharynx, hypopharynx, or larynx cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving paclitaxel and carboplatin before radiation therapy with paclitaxel may kill more tumor cells.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION intensity-modulated radiation therapy
- PROCEDURE quality-of-life assessment
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-12-26 |
| Est. Completion | 2017-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02048020
The ClinicalTrials.gov registry entry for NCT02048020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,422-participant average among 4 other Human Papilloma Virus Infection trials with a reported enrollment target (98% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Human Papilloma Virus Infection appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT02048020 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02048020 about?
NCT02048020 is a clinical study titled "Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer". This phase II trial studies how well paclitaxel and carboplatin before radiation therapy with paclitaxel works in treating human papillomavirus (HPV)-positive patients with stage III-IV oropharynx, hypopharynx, or larynx cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in...
What is the current status of trial NCT02048020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2013-12-26. Estimated completion is 2017-01-09.
What conditions does trial NCT02048020 study?
This clinical trial studies the following conditions: Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Hypopharynx.
What interventions are being tested in trial NCT02048020?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), intensity-modulated radiation therapy (RADIATION), quality-of-life assessment (PROCEDURE).
Who is sponsoring clinical trial NCT02048020?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02048020 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
COMPLETED · Phase 2
-
The Parents in Appalachia Receive Education Needed for Teen Project
ACTIVE NOT RECRUITING · NA
-
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
COMPLETED · Phase 3
Explore more on PlainTrial
Human Papilloma Virus Infection
All registered trials for this condition
Stage III Squamous Cell Carcinoma of the Oropharynx
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.